Defining regions of genomic imbalance can identify genes involved in tumour development. Conventional cytogenetics has identified several nonrandom copy number alterations (CNA) in uveal melanomas ...

Clinical testing using various array comparative genomic hybridization platforms is being incorporated rapidly into cytogenetic testing algorithms. Comprehensive validation of these complex assays ...

Comparative genomic hybridization (CGH) was developed to identify pathogenic DNA copy-number changes (e.g., duplications, deletions) on a genome-wide scale, and to map these changes to genomic ...

No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include a full text component.

Impact of BRCA1 gene alterations on tumor characteristics and clinical outcome in ovarian cancer (OC) patients. Background: Advanced ovarian clear cell carcinomas (OCCCs) are notoriously drug ...

Agilent Technologies Inc. has announced it has obtained worldwide, non-exclusive patent licenses from Abbott Molecular Inc. for the manufacture, marketing and sale of oligonucleotide microarrays using ...